<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01749150</url>
  </required_header>
  <id_info>
    <org_study_id>YV28218</org_study_id>
    <nct_id>NCT01749150</nct_id>
  </id_info>
  <brief_title>A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis</brief_title>
  <official_title>STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF RITONAVIR-BOOSTED DANOPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN IN TREATMENT-NAÏVE PATIENTS OF ASIAN ORIGIN WHO HAVE CHRONIC HEPATITIS C GENOTYPE 1 WITH OR WITHOUT COMPENSATED CIRRHOSIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This Phase II, open-label, parallel-arm study will evaluate the safety, tolerability,
      pharmacokinetics and antiviral activity of ritonavir-boosted danoprevir in combination with
      Pegasys (peginterferon alfa-2a) and Copegus (ribavirin) in treatment-naïve patients of Asian
      origin with chronic hepatitis C genotype 1. Patients will receive danoprevir 125 mg plus
      ritonavir 100 mg as fixed dose tablet orally twice daily in combination with weekly Pegasys
      180 mcg subcutaneously and Copegus 1000-1200 mg orally daily in divided doses. Treatment
      duration is 12 weeks in patients without cirrhosis and 24 weeks in patients with compensated
      cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 1.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve (AUC) for danoprevir/ritonavir</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral activity: Change in HCV RNA levels, measured using Roche COBAS TaqMan HCV Test v2.0 for High Pure System</measure>
    <time_frame>from baseline to Week 36/48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral activity: Proportion of patients with unquantifiable/undetectable HCV RNA during the study</measure>
    <time_frame>approximately 1.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of viral resistance to danoprevir</measure>
    <time_frame>approximately 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rapid virological response (RVR): Proportion of patients with undetectable HCV RNA at Week 4</measure>
    <time_frame>approximately 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete early virological response (cEVR): Proportion of patients with undetectable HCV RNA at Week 12</measure>
    <time_frame>approximately 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained virological response 12 weeks after end of treatment (SVR-12), defined as unquantifiable HCV RNA 8-20 weeks after the last day of study drug administration</measure>
    <time_frame>approximately 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained virological response 24 weeks after end of treatment (SVR-24), defined as unquantifiable HCV RNA &gt; 20 weeks after the last day of study drug administration</measure>
    <time_frame>approximately 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR measured as HCV RNA log10 IU/mL change from baseline to Week 12</measure>
    <time_frame>approximately 1.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>with cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>without cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danoprevir + ritonavir</intervention_name>
    <description>125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks</description>
    <arm_group_label>without cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>danoprevir + ritonavir</intervention_name>
    <description>125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks</description>
    <arm_group_label>with cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a [Pegasys]</intervention_name>
    <description>180 mcg sc weekly, 12 weeks</description>
    <arm_group_label>without cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>peginterferon alfa-2a [Pegasys]</intervention_name>
    <description>180 mcg sc weekly, 24 weeks</description>
    <arm_group_label>with cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin [Copegus]</intervention_name>
    <description>1000-1200 mg orally daily in divided doses, 12 weeks</description>
    <arm_group_label>without cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin [Copegus]</intervention_name>
    <description>1000-1200 mg orally daily in divided doses, 24 weeks</description>
    <arm_group_label>with cirrhosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients of East Asian or Southeast Asian origin, &gt;/= 18 years of age

          -  Presence of chronic genotype 1 hepatitis C infection

          -  Treatment-naïve

        Exclusion Criteria:

          -  History or presence of decompensated liver disease

          -  Presence or history of non-hepatitis C chronic liver disease

          -  Positive for hepatitis B or HIV infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiayi County</city>
        <zip>61363</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yunlin County</city>
        <zip>640</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2012</study_first_submitted>
  <study_first_submitted_qc>December 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2012</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Lactams</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

